{"id":58531,"date":"2026-03-02T13:29:20","date_gmt":"2026-03-02T05:29:20","guid":{"rendered":"https:\/\/flcube.com\/?p=58531"},"modified":"2026-03-02T13:29:20","modified_gmt":"2026-03-02T05:29:20","slug":"nmpa-cde-launches-caring-program-extension-pilot-accelerates-rare-disease-drug-development-pathway","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58531","title":{"rendered":"NMPA CDE Launches &#8220;Caring Program &#8211; Extension&#8221; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway"},"content":{"rendered":"\n<p>The <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> released the <strong>&#8220;Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases (&#8216;Caring Program &#8211; Extension&#8217;)&#8221;<\/strong>, now open for <strong>public feedback<\/strong> through March\u202f2026. The initiative establishes a <strong>structured pre\u2011pivotal trial pathway<\/strong> enabling sponsors to collaborate with regulators on <strong>rare disease clinical development frameworks<\/strong>, accelerating innovation for underserved patient populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-initiative-overview\">Regulatory Initiative Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Body<\/strong><\/td><td>Center for Drug Evaluation (CDE), NMPA<\/td><\/tr><tr><td><strong>Program Name<\/strong><\/td><td>&#8220;Caring Program &#8211; Extension&#8221; (\u5173\u7231\u8ba1\u5212\u00b7\u5ef6\u4f38)<\/td><\/tr><tr><td><strong>Program Type<\/strong><\/td><td>Pilot program for rare disease drug development<\/td><\/tr><tr><td><strong>Consultation Period<\/strong><\/td><td>One month (public feedback)<\/td><\/tr><tr><td><strong>Focus Stage<\/strong><\/td><td>Early development (prior to pivotal clinical trials)<\/td><\/tr><tr><td><strong>Core Mechanism<\/strong><\/td><td>Clinical Development Implementation Framework<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-mechanism\">Program Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Function<\/th><\/tr><\/thead><tbody><tr><td><strong>Framework Submission<\/strong><\/td><td>Applicants submit &#8220;Clinical Development Implementation Framework for Innovative Rare Disease Drugs&#8221; via formal CDE communication channels<\/td><\/tr><tr><td><strong>Development Plan Discussion<\/strong><\/td><td>CDE engages on indication\u2011specific development strategy<\/td><\/tr><tr><td><strong>Continuous Refinement<\/strong><\/td><td>Framework evolves as clinical research progresses<\/td><\/tr><tr><td><strong>Dedicated Dossier<\/strong><\/td><td>Serves as comprehensive clinical development record for specific rare disease indication<\/td><\/tr><tr><td><strong>Lifecycle Communication<\/strong><\/td><td>Facilitates ongoing, efficient CDE dialogue throughout R&amp;D<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eligibility-criteria\">Eligibility Criteria<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Criterion<\/th><th>Requirement<\/th><\/tr><\/thead><tbody><tr><td><strong>1. Rare Disease Indication<\/strong><\/td><td>Target indication must be classified as rare disease<\/td><\/tr><tr><td><strong>2. Strong Innovativeness<\/strong><\/td><td>Drug must demonstrate significant innovative characteristics<\/td><\/tr><tr><td><strong>3. Clinical R&amp;D Stage<\/strong><\/td><td>Development for target indication must be in clinical research phase (pre\u2011pivotal)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Innovation:<\/strong> The <strong>&#8220;source\u2011level&#8221; innovation focus<\/strong> addresses fundamental scientific challenges in rare disease drug development, moving beyond incremental improvements to <strong>novel mechanisms and targets<\/strong>.<\/li>\n\n\n\n<li><strong>Early Engagement Model:<\/strong> <strong>Pre\u2011pivotal CDE collaboration<\/strong> reduces regulatory uncertainty, enabling sponsors to <strong>optimize trial design<\/strong> and <strong>avoid late\u2011stage development failures<\/strong>\u2014critical for rare diseases with limited patient populations.<\/li>\n\n\n\n<li><strong>Lifecycle Dossier Concept:<\/strong> The <strong>continuously refined framework<\/strong> creates a <strong>living regulatory document<\/strong>, streamlining communication and potentially accelerating review timelines upon NDA submission.<\/li>\n\n\n\n<li><strong>Global Alignment:<\/strong> The program mirrors <strong>FDA&#8217;s Rare Disease Accelerator<\/strong> and <strong>EMA&#8217;s PRIority MEdicines (PRIME)<\/strong> initiatives, positioning China as a <strong>competitive jurisdiction<\/strong> for rare disease development.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-impact\">Industry Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Domestic Rare Disease Biotechs<\/strong><\/td><td>Structured pathway reduces regulatory risk; encourages investment in novel rare disease targets<\/td><\/tr><tr><td><strong>Multinational Pharma<\/strong><\/td><td>China\u2011first or parallel development strategies now viable for rare disease assets with CDE engagement<\/td><\/tr><tr><td><strong>Patient Advocacy Groups<\/strong><\/td><td>Accelerated development timelines improve access to innovative therapies for underserved populations<\/td><\/tr><tr><td><strong>Investors<\/strong><\/td><td>Regulatory clarity enhances valuation confidence for rare disease development programs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding pilot program implementation, framework adoption rates, and rare disease approval timelines. Actual results may differ due to risks including program uptake variability, CDE resource constraints, and scientific validation challenges in novel rare disease mechanisms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u7f55\u89c1\u75be\u75c5\u521b\u65b0\u836f\u7269\u7814\u53d1\u9f13\u52b1\u8bd5\u70b9\u8ba1\u5212\uff08\u5173\u7231\u8ba1\u5212-\u5ef6\u4f38\uff09\u4ecb\u7ecd.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u7f55\u89c1\u75be\u75c5\u521b\u65b0\u836f\u7269\u7814\u53d1\u9f13\u52b1\u8bd5\u70b9\u8ba1\u5212\uff08\u201c\u5173\u7231\u8ba1\u5212-\u5ef6\u4f38\u201d\uff09\u4ecb\u7ecd.\"><\/object><a id=\"wp-block-file--media-cc0952f6-0e3f-4171-bd2f-735fc38cc865\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u7f55\u89c1\u75be\u75c5\u521b\u65b0\u836f\u7269\u7814\u53d1\u9f13\u52b1\u8bd5\u70b9\u8ba1\u5212\uff08\u5173\u7231\u8ba1\u5212-\u5ef6\u4f38\uff09\u4ecb\u7ecd.pdf\">\u7f55\u89c1\u75be\u75c5\u521b\u65b0\u836f\u7269\u7814\u53d1\u9f13\u52b1\u8bd5\u70b9\u8ba1\u5212\uff08\u201c\u5173\u7231\u8ba1\u5212-\u5ef6\u4f38\u201d\uff09\u4ecb\u7ecd<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u7f55\u89c1\u75be\u75c5\u521b\u65b0\u836f\u7269\u7814\u53d1\u9f13\u52b1\u8bd5\u70b9\u8ba1\u5212\uff08\u5173\u7231\u8ba1\u5212-\u5ef6\u4f38\uff09\u4ecb\u7ecd.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cc0952f6-0e3f-4171-bd2f-735fc38cc865\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) released the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[14,24],"class_list":["post-58531","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nmpa","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA CDE Launches &quot;Caring Program - Extension&quot; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) released the &quot;Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases (&#039;Caring Program - Extension&#039;)&quot;, now open for public feedback through March\u202f2026. The initiative establishes a structured pre\u2011pivotal trial pathway enabling sponsors to collaborate with regulators on rare disease clinical development frameworks, accelerating innovation for underserved patient populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58531\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA CDE Launches &quot;Caring Program - Extension&quot; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) released the &quot;Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases (&#039;Caring Program - Extension&#039;)&quot;, now open for public feedback through March\u202f2026. The initiative establishes a structured pre\u2011pivotal trial pathway enabling sponsors to collaborate with regulators on rare disease clinical development frameworks, accelerating innovation for underserved patient populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58531\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T05:29:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58531#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58531\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA CDE Launches &#8220;Caring Program &#8211; Extension&#8221; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway\",\"datePublished\":\"2026-03-02T05:29:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58531\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NMPA\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58531#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58531\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58531\",\"name\":\"NMPA CDE Launches \\\"Caring Program - Extension\\\" Pilot \u2013 Accelerates Rare Disease Drug Development Pathway - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-02T05:29:20+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released the \\\"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program - Extension')\\\", now open for public feedback through March\u202f2026. The initiative establishes a structured pre\u2011pivotal trial pathway enabling sponsors to collaborate with regulators on rare disease clinical development frameworks, accelerating innovation for underserved patient populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58531#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58531\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58531#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA CDE Launches &#8220;Caring Program &#8211; Extension&#8221; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA CDE Launches \"Caring Program - Extension\" Pilot \u2013 Accelerates Rare Disease Drug Development Pathway - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released the \"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program - Extension')\", now open for public feedback through March\u202f2026. The initiative establishes a structured pre\u2011pivotal trial pathway enabling sponsors to collaborate with regulators on rare disease clinical development frameworks, accelerating innovation for underserved patient populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58531","og_locale":"en_US","og_type":"article","og_title":"NMPA CDE Launches \"Caring Program - Extension\" Pilot \u2013 Accelerates Rare Disease Drug Development Pathway","og_description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released the \"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program - Extension')\", now open for public feedback through March\u202f2026. The initiative establishes a structured pre\u2011pivotal trial pathway enabling sponsors to collaborate with regulators on rare disease clinical development frameworks, accelerating innovation for underserved patient populations.","og_url":"https:\/\/flcube.com\/?p=58531","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T05:29:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58531#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58531"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA CDE Launches &#8220;Caring Program &#8211; Extension&#8221; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway","datePublished":"2026-03-02T05:29:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58531"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NMPA","Rare \/ orphan disease drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58531#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58531","url":"https:\/\/flcube.com\/?p=58531","name":"NMPA CDE Launches \"Caring Program - Extension\" Pilot \u2013 Accelerates Rare Disease Drug Development Pathway - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-02T05:29:20+00:00","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) released the \"Pilot Program for Encouraging the Development of Innovative Drugs for Rare Diseases ('Caring Program - Extension')\", now open for public feedback through March\u202f2026. The initiative establishes a structured pre\u2011pivotal trial pathway enabling sponsors to collaborate with regulators on rare disease clinical development frameworks, accelerating innovation for underserved patient populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58531#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58531"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58531#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA CDE Launches &#8220;Caring Program &#8211; Extension&#8221; Pilot \u2013 Accelerates Rare Disease Drug Development Pathway"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58531"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58531\/revisions"}],"predecessor-version":[{"id":58533,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58531\/revisions\/58533"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}